Tom John

17PUBLICATIONS

176CO-AUTHORS

Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Rehabilitation

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (17)

Sort by Publication Date:

|Jun 26, 2026

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

|Feb 18, 2026

Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer.

Rachel Woodford, Sally Lord, Tom John

|Sep 11, 2025

Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.

Adithya Balasubramanian, Claire Marceaux, Sehrish Kanwal

|Sep 09, 2025

Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet

|Apr 16, 2025

Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non-Small Cell Lung Cancer.

Deborah Di-Xin Zhou, Janene Dalrymple, Danielle Klingberg

|Mar 18, 2025

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.

Roy S Herbst, Thomas John, Christian Grohé

Pageof 3

Frequent Collaborators

James Chih-Hsin Yang

Yi-Long Wu

Ji-Youn Han

Luis Paz-Ares Rodriguez

Enriqueta Felip

Myung-Ju Ahn

Wendy A Cooper

Lyudmila Bazhenova

Ian Marschner

Sarah J Lord

Frequent Collaborators

James Chih-Hsin Yang

Yi-Long Wu

Ji-Youn Han

Luis Paz-Ares Rodriguez